Status:

RECRUITING

Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

Lead Sponsor:

Proton Collaborative Group

Collaborating Sponsors:

University of Florida Health

Conditions:

Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to see what effects, good and/or bad, proton radiation, and/or conventional radiation and hormonal therapy (if applicable), has on prostate cancer that has already returne...

Eligibility Criteria

Inclusion

  • Prostate cancer treated primarily with open, laparoscopic or robotically assisted prostatectomy.
  • Maximum PSA value of 20 ng/ml.

Exclusion

  • Evidence of distant metastasis (M1).
  • Prior systemic chemotherapy for any reason.
  • Previous irradiation to the pelvis that would compromise the ability to deliver the prescribed study treatment.
  • Active inflammatory bowel disease (Crohn's disease, diverticulitis or ulcerative colitis) affecting the rectum. (Non-active diverticulitis and Crohn's disease not affecting the rectum are allowed).
  • History of hip replacement.
  • Prior or concurrent cancer, other than non-melanomatous skin cancer, unless disease free for at least 5 years.
  • Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.

Key Trial Info

Start Date :

August 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2050

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT00969111

Start Date

August 1 2009

End Date

August 1 2050

Last Update

September 9 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Proton Center of Arkansas

Little Rock, Arkansas, United States, 72205

2

University of Florida Proton Therapy Institute

Jacksonville, Florida, United States, 32206

3

Northwestern Medicine Chicago Proton Center

Warrenville, Illinois, United States, 60555

4

Inova Schar Cancer Institute

Fairfax, Virginia, United States, 22031